About US
Contact us
-
Novartis seeks to revive Neulasta biosim prospects with data showing it matches Amgen’s blockbusterThe FDA dealt Novartis’Sandoz unit a blow last summer when it issued a complete response letter for the company’s biosimilar version of Amgen’s blockbuster drug Neulasta (pegfilgrastin). The Swiss dru2018/3/9
-
Activists press Alexion for stepped-up guidance, boardroom edits: reportThanks to recent "turmoil" at the company, Leerink Partners analyst Geoffrey Porges has called Alexion“one of the rare, once or twice per decade, activist investment situations in the biopharmaceutica2017/12/8
-
Pfizer's legendary Viagra finally set to face cheaper competition in U.S.All these years after its initial approval, Pfizer's little blue pill Viagra is coming to the end of its patent life.Still, the company has plans to keep its key med churning. The drugmaker on2017/12/7
-
Can Roche's Tecentriq leapfrog rival meds in lung cancer? Jury's still outOn Thursday, Rocheunveiledpositive results from its first-line lung-cancer combo trial—but those results raised more questions than they provided answers. Adding PD-L1 drug Tecentriq to a combinati2017/12/7
-
Johnson & Johnson, Sanofi top 'Good Pharma' trial transparency ranking with perfect scoresIt’s an A-plus for Johnson & Johnson and Sanofi. The second annual Good Pharma Scorecard assigned both drugmakers perfect scores of 100% for clinical trial transparency. AbbVie, Celgene, Merck and2017/12/6
-
In Supreme Court petition, Merck argues that FDA power shields against liabilityYears after suing drug giant Merck & Co. for serious injuries allegedly caused by osteoporosis drug Fosamax, more than 500 plaintiffs will have to wait to hear the U.S. Solicitor General's take2017/12/6
-
Amgen gets its shot at promoting Repatha to prevent heart attacks and strokesAmgen has its long-awaited approval to tout Repatha as a cardiovascular prevention tool. On the basis ofamassive CV outcomes trial unveiled in March, the FDA blessed the cholesterol drug to fend off h2017/12/5
-
As Johnson & Johnson holds off U.S. biosims, Remicade's European market share falls to 50%: reportJohnson & Johnson’s blockbuster anti-TNF drug Remicade fell victim to biosimilar competition in Europe in 2015 and in the U.S. last year, but the impact of the inexpensive copycat drugs has been q2017/12/5
-
Pfizer tops Dow's intellectual heap, with J&J and Merck close behind: studyPfizer is the smartest company in the Dow. That’s according to Talent Growth Advisors' annualassessmentof the 30 companies that make up the Dow Jones Industrial Average. The organization uses an ac2017/12/4
-
Lilly's Taltz takes Cosentyx rivalry into psoriatic arthritis with new FDA nodEli Lilly’s Taltz officially has a new arena where it can challenge Novartis’ Cosentyx. On Friday, the FDAgrantedthe immunology drug a green light in psoriatic arthritis, a condition that affects a2017/12/4